On September 16, 2022 EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, reported the appointment of Dr Amir Snapir as Chief Medical Officer (CMO), effective 21 September 2022 (Press release, Exact Therapeutics, SEP 16, 2022, View Source [SID1234619605]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to welcome Amir to EXACT-Tx as CMO. His extensive experience in clinical development and thorough understanding of the regulatory and clinical framework for drug-device combinations will be pivotal for our further development of ACT.", said Dr Per Walday, CEO of EXACT-Tx. "We continue to build a strong organisation with clinical and regulatory expertise for excellence in development strategy and execution. We are very happy to have Amir in this critical leadership role for the future development of ACT".
Dr Snapir has a PhD from the University of Turku, Finland and an MD from the University of Tel Aviv, Israel. He has extensive experience in global clinical development of novel therapeutics, from early clinical translation to marketing authorisation, combined with extensive international regulatory experience. Dr Snapir also has years of experience in business collaborations, alliances and product co-developments. Dr Snapir comes from the position as CMO of PCI Biotech where he was responsible for the clinical development of drug-device combination product candidates. From 2007 to 2020 he held various positions at Orion Pharma, Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical development leader in Oncology. Dr Snapir is the author of numerous scientific publications.